Tyra Biosciences expands at-the-market stock program to $250 million

Tyra Biosciences filed a prospectus supplement on August 4, 2026 to update its existing at-the-market equity program. The company had previously entered a sales agreement dated May 8, 2025 with TD Securities (USA) LLC, doing business as TD Cowen, covering the offering and sale of up to $150,000,000 of common stock through or to TD Cowen as sales agent or principal.¹

As of the date of this prospectus supplement, Tyra had sold the full $150,000,000 available under that agreement.¹

On August 4, 2026, the company entered an amendment to the sales agreement to raise the maximum aggregate offering price it may sell, subject to limits tied to what is registered on an effective registration statement and covered by a prospectus or prospectus supplement filed before the offering begins.¹ After the amendment and this supplement, Tyra may offer and sell up to an aggregate of $250,000,000 of common stock.¹

Tyra's common stock trades on the Nasdaq Global Select Market under the ticker "TYRA".¹ The last reported sale price on August 3, 2026 was $32.04 per share.¹

The supplement is tied to Tyra's broader shelf registration. It updates and supplements the sales agreement prospectus originally filed with the SEC on May 8, 2025 and dated May 16, 2025, part of a Form S-3 registration statement.¹

The filing directs investors to risk factors beginning on page 8 of the original prospectus, as well as risks described in Tyra's most recent Annual Report on Form 10-K and any Quarterly Reports on Form 10-Q filed since.¹ Neither the SEC nor any state securities commission has approved or disapproved of the securities, and any representation to the contrary is stated to be a criminal offense.¹